RESEARCH ARTICLE

Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation

Junxiang Zhou1*, Yixin Wang2, Gang Jiang1

1 Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, 2 Department of Operations Management, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

* zhoujunxiang87@126.com

Abstract

Objective

To evaluate the efficacy, safety and cost-effectiveness of Oxycodone Hydrochloride Controlled-release Tablets (CR oxycodone) and Morphine Sulfate Sustained-release Tablets (SR morphine) for moderate to severe cancer pain titration.

Methods

Randomized controlled trials meeting the inclusion criteria were searched through Medline, Cochrane Library, Pubmed, EMBase, CNKI, VIP and WanFang database from the data of their establishment to June 2019. The efficacy and safety data were extracted from the included literature. The pain control rate was calculated to estimate efficacy. Meta-analysis was conducted by Revman5.1.4. A decision tree model was built to simulate cancer pain titration process. The initial dose of CR oxycodone and SR morphine group were 20mg and 30mg respectively. Oral immediate-release morphine was administered to treat break-out pain. The incremental cost-effectiveness ratio was performed with TreeAge Pro 2019.

Results

19 studies (1680 patients) were included in this study. Meta-analysis showed that the pain control rate of CR oxycodone and SR morphine were 86% and 82.98% respectively. The costs of CR oxycodone and SR morphine were $23.27 and $13.31. The incremental cost-effectiveness ratio per unit was approximate $329.76. At the willingness-to-pay threshold of $8836, CR oxycodone was cost-effective, while the corresponding probability of being cost-effective at the willingness-to-pay threshold of $300 was 31.6%. One-way sensitivity analysis confirmed robustness of results.

Conclusions

CR oxycodone could be a cost-effective option compared with SR morphine for moderate to severe cancer pain titration in China, according to the threshold defined by the WHO.
Introduction

Pain affects cancer patients at all stages from diagnosis to palliative care and is one of the most feared and burdensome symptoms [1,2]. It has a substantial impact on both the clinical and humanistic burden of cancer, particularly in the developing regions of the world [3]. Moderate to severe pain is experienced by more than one third of patients with advanced cancer [4]. Cancer pain is the major factor of influencing the life quality of cancer patients so alleviating pain is of great significance for the treatment of cancer. For the past 30 years cancer pain has been managed according to the World Health Organization (WHO) analgesic ladder [5].

The three-step ladder recommends sequential increases in the strength of analgesia, starting with non-opioid, adding in a weak opioid and finally progressing to a strong opioid until adequate pain relief with minimal adverse drug reaction. In an open-label multicenter randomized control trial, Oxycodone Hydrochloride Controlled-release Tablets (CR oxycodone) and Morphine Sulfate Sustained-release Tablets (SR morphine) were shown to have no differences in tolerability and efficacy as first-line treatment for moderate to severe cancer pain [6]. However, a cochrane review of twenty-three randomized clinical trials indicated that pain relief was significantly better after treatment with SR morphine than CR oxycodone (SMD 0.14, 95% CI 0.01 to 0.27) for cancer pain [7].

In most patients, oral medications should be used initially because they are noninvasive, convenient, and easy to titrate. Opioid-naïve patients experiencing moderate to severe pain should receive rapid titration of oral 5-15mg morphine or equivalent at initial dose. After sixty minutes, efficacy and adverse effects should be reassessed to determine whether to escalate dose by 50%-100% or repeat the same dose [8]. In cancer pain management sustained-release opioids are used for continuous pain as well as immediate-release opioids for break-out pain [9]. The European Association for Palliative Care research network recommend that both of CR oxycodone and SR morphine could be used to titrate in initial treatment of cancer pain [10]. CR oxycodone offers a biphasic absorption pattern which is consist of an initial rapid onset followed by a prolonged phase. In addition, CR oxycodone and SR morphine require twice-daily(every 12hours a day) dosing compared with traditional titration strategy(four times daily), greatly enhancing their administration in cancer pain titration [11].

Most studies comparing oral morphine and oxycodone were conducted in patients who had already a favorable response to opioid treatment [7,12,13], so they could not conclude which one of the two drugs can be considered superior to the other when used as “cancer pain titration” in clinical practice. A cost analysis of CR oxycodone for cancer pain management in Brazil demonstrated that CR oxycodone could lead to a reduction in total costs related to pain treatment in patients with cancer(392.66 BRL per patient), which would lead to resource savings for the payer [14]. Therefore, the costs are another important aspect to impact clinical treatment decision and rational drug use. However, few published data about the percentage of total medical costs associated with cancer attributable to cancer pain titration can be obtained [15]. On this basis, we launched this study aimed at exploratory assessing the efficacy, safety and cost-effectiveness of CR oxycodone and SR morphine applied in the titration of moderate to severe cancer pain.

Methods

We conducted an incremental cost-effectiveness analysis based on a decision tree for two titration strategies: CR oxycodone group and SR morphine group. We also conducted a meta-analysis of randomized control trials comparing CR oxycodone and SR morphine to obtain efficacy and safety data. The costs data of two group derived from medicine purchasing price of our hospital. Cancer pain was a complication during cancer therapy, so only direct medical
costs were considered, excluding the direct non-medical costs (e.g. transportation costs) and indirect cost (e.g. the loss of productivity). All costs were expressed in Chinese yuan (¥), year 2017 values. The costs were translated to dollar at the rate of $1 = ¥6.7518 (as of 2017) [16].

Model structure and assumptions
The structure of the model is shown in Fig 1. This model structure was built upon three assumptions according to NCCN Clinical Practice Guidelines in Oncology of Adult Cancer Pain: (1) The initial dose of CR oxycodone was 20mg. (2) The equivalences of oxycodone compared with morphine based on single-dose was 1:1.5. (3) Oral immediate-release morphine was administered to treat break-out pain [8]. The dose equivalent to 12.5% of total opioid taken in the previous 24h. We developed a decision tree model with a cycle length of 72 hours. The cycle length of 72 hours was chosen because titration should be finished as soon as possible within 48–72 hours recommended by the WHO [17]. This model structure simulated titration of opioid. At the beginning, patients were randomized to either CR oxycodone group or SR morphine group, receiving CR oxycodone 20mg q12h and SR morphine 30mg q12h respectively. If the times of break-out pain exceeded 3 within 24h, dose of CR oxycodone was increased to 40mg q12h as well as SR morphine to 60mg q12h in next 24h. If break-out pain still exceeded 3 times within the second 24h, dose of CR oxycodone was increased to 60mg q12h as well as SR morphine to 90mg q12h in the third 24h. The model cycle was closed whether cancer pain was succeed titration or not after the third 24h. Patients that were titrated successfully in any time can maintain current dose until model cycle closed.

![Decision tree model for moderate to severe cancer pain titration.](https://doi.org/10.1371/journal.pone.0231763.g001)
Study selection and meta-analysis

We searched Medline, Cochrane clinical trials database, Embase, Pubmed, CNKI, VIP and WangFan database from establishment to June 2019. The search strategy included the following keywords: oxycodone, morphine, neoplasm and randomized control trial, combined with free-word retrieval from Mesh and Emtree. Two authors independently finished selection of articles by reading titles, abstracts, full texts or both of them. For some unclear articles, we contacted original authors to identify details by e-mail or telephone. Disagreements were resolved by consensus. The inclusion criteria included: (1) literatures should be designed as randomized controlled trials, (2) the aim population was cancer pain patients, (3) one group used oral CR oxycodone to titrate, another group used oral SR morphine to titrate, (4) Numeric rating scales(NRS) score of cancer pain $\geq 4$, (5) immediate-release morphine was used to treat breakthrough pain. We excluded studies: (1) cancer pain titration process was not mentioned, (2) immediate-release oxycodone or morphine were used to titrate, (3) patients received either CR oxycodone or SR morphine combined with other opioids or non-steroidal anti-inflammatory drugs, (4) data on the main outcomes were unavailable.

Data were extracted independently by two reviewers using a standardized collection form. Data from eligible studies were pooled to determine the pain control rate and the rate of adverse drug reaction. The outcomes of pain control rate were divided into 24h pain control rate, 48h pain control rate and 72h pain control rate. The data of adverse drug reaction came from all outcomes of eligible studies reported, such as constipation, nausea, vomiting, pruritus, urinary retentron and anorexia. Meta-analysis was performed by Review Manager 5.1.4 which was the Cochrane Collaboration recommendation software. We tested for heterogeneity with significance set at $p < 0.10$ or $I^2 > 50\%$ using the Chi-squared($\chi^2$) test and random effect model was used to calculated $[18]$. Fixed effect model was used to calculated conversely. The Mantel-Haenszel test was used to estimate risk ratio(RR) and 95% confidence intervals(95%CI). A p-value of less than 0.05 for the test indicated statistically significant heterogeneity.

Assessment of risk of bias in included studies

According to Cochrane Collaboration Handbook 5.1.0 version, quality assessment was made of all included studies, to consider the following questions: (1) Was the assessment to treatment groups truly random? (2) Was allocation adequately concealed? (3) Were those assessing outcomes or blind to the treatment allocation? (4) How were the outcomes considered for people who withdrew and dropout? (5) Were the resemblance between treatment group and control group? (6) Was there any interest conflict bias $[18]$? The Cochrane Collaboration Handbook criteria are based on the evidence of a strong relationship between the potential bias in the results and methods quality which defined as below: Yes-low risk of bias(adequate); Unclear-moderate risk of bias(some doubt about the result); NO-high risk of bias(inadequate). We contacted authors of all the included studies to acquire details as possible. Publication bias was assessed through testing funnel plot asymmetry which should be interpreted in the light of visual inspection of the funnel plot $[18]$.

Costs of cancer pain titration and adverse drug reactions

Two types of costs were included in the model: costs associated with cancer pain titration and adverse drug reactions. Costs of cancer pain titration consisted of CR oxycodone, SR morphine and morphine hydrochloride tablets. Following the included paper, we considered only adverse drug reactions that occurred in $>1\%$ of each group, such as vomiting, nausea, constipation, pruritus. The probabilities of occurrence of adverse drug reactions were derived from our included studies. The costs of adverse drug reactions were calculated as incidence of
adverse drug reactions multiplied by costs of medicine for corresponding events. The resource utilization was estimated based on patient records reviewed at the Sichuan cancer hospital. We adopted phenolphthalein, metoclopramide, diphenhydramine, megestrol and catheterization to manage constipation, emesis, pruritus, anorexia and urinary retention respectively. The total costs of cancer pain titration and adverse drug reactions were estimated based on official pricelist of National Health Commission of P.R. China. Detailed information of unit costs were shown in Table 1. The costs of cancer pain titration and adverse drug reactions were shown in Table 2. The outcomes of measures for the model were the total costs including CR oxycodone titration costs, SR morphine titration costs and adverse drug reactions costs correspondingly in 2017 Chinese yuan (¥).

**Cost-effectiveness analysis based on a decision tree**

The decision-tree-based incremental cost-effectiveness analysis was performed with Decision Tree Software (TreeAge Pro 2019). The events examined in the decision tree were pain controlled rate while receiving opioid titration within model cycle. The probabilities used in the decision tree were determined from the meta-analysis of efficacy and safety. The costs used in the decision tree were those determined in our analysis of the costs of treatment and adverse drug reactions. Incremental cost-effectiveness ratio for the incremental cost per unit gained with each titration strategy were calculated using the formula: ICER = (Co-Cm)/(Eo-Em), where Co and Eo were the costs and pain control rate of CR oxycodone and Cm and Em were the costs and pain control rate of SR morphine.

In the absence of specific utility value for cancer pain titration, we used pain control rate to estimate efficacy. According to NRS score: 0 refers painless; 1–3 refers to mild pain; 4–6 refers to moderate pain; 7–10 refers to severe pain [8]. The criteria of analgesic efficacy evaluation included: (1) complete remission: painless, (2) partial remission: NRS score down to 1–3, (3) mild remission: NRS score down to 4–6, (4) non-remission: stable or incremental NRS score. Pain control rate = (case of complete remission + case of partial remission)/all case.

To examine the stability of the model to alternative input parameters and assumptions, we conducted sensitivity analysis. Here, individual parameters were varied independently with the usual convention being that both a value less than and a value higher than the base-case input parameters were tasted. We summarized the results of sensitivity analysis by examining the effect of changing parameter values or assumptions on the total costs of treatment. Monte

| Resource                              | Costs(¥) |
|---------------------------------------|----------|
| **Medicine for cancer pain titration**|          |
| Controlled-release Oxycodone 10mg    | 9.5      |
| Sustained-release Morphine 10mg       | 4.5      |
| Sustained-release Morphine 30mg       | 9.9      |
| Morphine Hydrochloride Tablet 5mg     | 0.865    |
| **Medicine for adverse drug reactions treatment** | |
| Phenolphthalein Tablet 100mg          | 0.03     |
| Metoclopramide Tablet 5mg             | 0.03     |
| Diphenhydramine Hydrochloride Tablet 25mg | 0.02 |
| Megestrol Acetate Dispersible Tablet 160mg | 10.43 |
| Nursing                               | 12       |
| Urethral catheter per set             | 16.72    |

https://doi.org/10.1371/journal.pone.0231763.t001
Carlo Simulation was conducted to analysis sensitivity of probability [19,20]. Cost-effectiveness acceptability curve and cost-effectiveness scatterplot were displayed.

**Results**

**Paper selection and quality assessment**

The search identified 1401 papers; after duplicates were removed, 782 papers remained, with 81 papers included for full-text review, and 19 papers (1680 patients) were included in this study [21–39]. Of the excluded papers, 20 papers adopted neither CR oxycodone nor SR morphine as comparison group. The way of cancer pain titration reported in 23 papers could not meet our model, such as subcutaneous administration, drug combination, dosage reversed and cancer pain assessment with visual analog scale. 17 papers did not report original data which our study concern. 2 papers were excluded because the adverse drug reaction data were noted as score. A flow chart describing study selection was presented in Fig 2. The risk of bias graph and the risk of bias summary for the included studies were described in Fig 3, Fig 4. The funnel plots for assessment of publication bias were showed in Figs 5–10.

**Efficacy and safety**

Two studies reported the pain control rate (97 patients) [36,38]. There were no significant difference between CR oxycodone and SR morphine for moderate to severe cancer pain titration in 24h ($I^2 = 0$, RR = 1.11, 95%CI[0.81,1.51], p = 0.53), 48h ($I^2 = 0$, RR = 0.86, 95%CI[0.41,1.80], p = 0.69) and 72h ($I^2 = 0$, RR = 1.33, 95%CI[0.40,4.49], p = 0.64). The pain control rate of CR oxycodone for moderate to severe cancer pain titration in 24h, 48h and 72h were 64%, 38.89% and 36.36% respectively. As for SR morphine, the pain control rate were 57.45%, 45% and 27.27% respectively. All of the included studies reported adverse drug reactions. CR oxycodone titration resulted fewer constipation(19.09% vs. 29.63%, p<0.00001) and nausea/vomiting(21.7% vs. 27.4%, p = 0.004) than SR morphine titration, but the probability of pruritus (7.67% vs. 7.79%, p = 0.99), urinary retention (1.05% vs. 3.01%, p = 0.09) and anorexia (3.07% vs. 3.25%, p = 0.97) were not shown significant difference. (Table 3).

**Total costs**

The total costs of CR oxycodone group and SR morphine group were calculated at the events of 24h, 48h, 72h pain control and pain control failure after 72h separately. For each events, the

| Resource                        | CR oxycodone group | SR morphine group |
|---------------------------------|--------------------|-------------------|
| Cancer pain titration           |                    |                   |
| 24h pain control                | 114.00             | 59.40             |
| 48h pain control                | 195.19             | 104.19            |
| 72h pain control                | 243.57             | 134.37            |
| Pain control failure            | 259.14             | 149.94            |
| Adverse drug reactions treatment|                    |                   |
| Constipation                    | 0.02               | 0.03              |
| Nausea and vomiting             | 0.08               | 0.10              |
| Pruritus                        | 0.02               | 0.02              |
| Urinary retention               | 0.30               | 0.86              |
| Anorexia                        | 0.64               | 0.68              |

https://doi.org/10.1371/journal.pone.0231763.t002
total costs of CR oxycodone group were higher than SR morphine group. Comparing CR oxycodone with SR morphine, the total costs in 24h, 48h, 72h and pain control failure were $17.04 vs. $9.05, $29.07 vs. $15.68, $36.23 vs. $20.15 and $38.54 vs. $22.46 respectively (Table 4).

![Flow chart of study selection](https://doi.org/10.1371/journal.pone.0231763.g002)

![Risk of bias graph](https://doi.org/10.1371/journal.pone.0231763.g003)
Fig 4. Risk of bias summary.

https://doi.org/10.1371/journal.pone.0231763.g004
Cost-effectiveness analysis based on a decision tree

The result of cost-effectiveness analysis showed that the costs per patient for cancer pain titration with CR oxycodone was $23.27, while the costs was $13.31 by using SR morphine. The pain control rate of cancer pain titration were 86.00% and 82.98% by using CR oxycodone and SR morphine respectively (Table 5). The ICER value was $329.76 per unit. Thousand samples were calculated by using Monte Carlo Simulation for our established decision tree. The simulation running results were shown as cost-effectiveness acceptability curve (Fig 11) and cost-effectiveness scatter plot (Fig 12). The probability of ICER per unit below $300, $400, $500 and $600 were 31.6%, 73.8%, 90.9% and 96.7% respectively.

Alternative assumptions and parameters were investigated in sensitivity analysis. Three titration strategies were used to change the research assumption to test the stability of the results. If the initial titration dose of CR oxycodone is set at 10mg, the costs of CR oxycodone will reduced to a similar level of SR morphine (Table 6). The ICER per unit of CR oxycodone compared with SR morphine were $348.05, $0.63 and $0.51 at titration dose of CR oxycodone 20mg-40mg-80mg strategy, 10mg-20mg-30mg strategy and 10mg-20mg-40mg strategy respectively. With regard to changing of costs, the one-way sensitivity analysis showed that an increasing of 100% in CR oxycodone acquisition costs, the ICER per unit increased to $1064.13. Other alternative parameters were used that increased of 15% in CR oxycodone acquisition costs, reduced of 15% in SR morphine acquisition costs, increased of 100% in adverse drug reactions treatment costs and reduced of 50% in adverse drug reaction treatment.
costs. The above mentioned variation of input parameter displayed minimal impact on the ICER.

Discussion

This is the first study to evaluate the economic of CR oxycodone compared with SR morphine in the treatment of cancer pain titration based on a decision tree model. Decision tree model increasingly use cost-effectiveness analysis to inform decision making on competing health care interventions. Economic models facilitate these analysis by providing a framework to combine information from different sources and enable probabilistic estimations. Our cost-effectiveness analysis based on a decision tree model predicted the benefits of CR oxycodone compared with SR morphine for moderate to severe cancer pain titration. The relative costs of cancer pain therapies has become an increasingly important issue in recent years due to growing concerns about the rising costs of health care and the lack of data demonstrating the superiority of one agent over another.

In our modeling analysis, CR oxycodone had higher efficiency than SR morphine in the treatment of moderate to severe cancer pain titration (86% vs. 82.98%), while had more expensive costs ($23.27 vs. $13.31). The willingness-to-pay (WTP) threshold has not been officially defined in China, the general consensus is to be set at 1 gross domestic product (GDP) per capita, which is defined by the WHO [40]. Our model showed that CR oxycodone could be considered cost-effective compared with SR morphine in terms of ICER per unit below the 1GDP of P.R. China in 2017 ($8836) [16]. Due to higher costs, CR oxycodone could not be deemed to
be cost-saving. The probability sensitivity analysis demonstrated that the probability of CR oxycodone being cost-effective at the WTP threshold of $300 and $600 was 31.6% and 96.7% respectively. Considering the heavy economic burden for patients associated with cancer treatment especially in antineoplastic drugs, the WTP of cancer pain titration may far less than 1GDP in developing country. SR morphine would be still a good choice for patient in financial straits. As a result of unique drug release technology of CR oxycodone, CR oxycodone may be better than SR morphine in cancer pain titration, but there was no evidence to support it. At our knowledge, this is the first pharmacoeconomic study to support that perspective. The economic model established in this study can be generalized to other countries for cost-effectiveness analysis of opioid titration by inputting local data.

For one-way sensitivity analysis, we further assumed that titration strategy would change in real world treatment. Three different titration strategies were tested in the model: (1) Day1 (CR oxycodone20mg, SR morphine30mg)-Day2 (CR oxycodone40mg, SR morphine60mg)-Day3(CR oxycodone80mg, SR morphine120mg), (2) Day1 (CR oxycodone10mg, SR morphine20mg)-Day2 (CR oxycodone20mg, SR morphine40mg)-Day3(CR oxycodone30mg, SR morphine60mg), (3) Day1 (CR oxycodone10mg, SR morphine20mg)-Day2 (CR oxycodone20mg, SR morphine40mg)-Day3(CR oxycodone40mg, SR morphine80mg). Despite this, CR oxycodone remained cost-effective. In addition, drug-acquisition costs was another crucial factor. Whether CR oxycodone price raised by 100%,15% or SR morphine price decreased by 15%, the ICER per unit still below the 1GDP of P.R. China in 2017($8836). Due to low costs of drugs to treat opioid adverse reactions in China, it had little impact on outcomes in spite of
increasing 100% or decreasing 50% the costs of adverse drug reactions. Hence, one-way sensitivity analysis demonstrated CR oxycodone was a cost-effective choice.

It is true that there are methodological problems and a plethora of extraneous variables that influence the reliability and validity of studies conducted in pharmacoeconomic area [3]. Some limitations of our study need to be taken into account when interpreting the results. First, the use of efficacy data from two randomized control trials [36,38] may limit the ability to generalize the findings of this analysis to a broader population, and more up-to-date clinical data may be available. Patients with cancer pain often receive concurrent chemotherapy or radiotherapy, which also have several side effects that can interfere with observation results of opioid adverse drug reactions. Most of the included studies did not describe whether patients received chemotherapy or radiotherapy during the cancer pain titration. In addition, the included studies in our analysis did not have exactly the same titration strategy and course of treatment that may effect on adverse drug reaction rate and costs estimating. To account for such differences, we conducted several sensitivity analysis. We changed our assumptions of titration strategy to another three common modes and found CR oxycodone remained cost-effective in these conditions. These titration strategies were discussed with clinical experts and were considered reasonable.

Furthermore, the drug-acquisition costs of moderate to severe cancer pain titration were calculated. Due to the cancer pain was a complication in the cancer therapy, the cancer pain titration was implemented in conjunction with chemotherapy or radiotherapy. The other hospitalization costs such as bed fee, chemotherapy fee, radiotherapy fee and indirect costs were not included in our analysis. It is difficult to accurately quantify these costs especially in

![Funnel plot of pruritus](https://doi.org/10.1371/journal.pone.0231763.g008)
developing countries where there are limited research and data [3]. Considering the influence of drug price on results, we attempted to ascertain the impact of parameter variation via alternatives in a one-way sensitivity analysis. In all the alternative scenarios conducted, the results were stable and consistent with base-case analysis. In Mexico, the costs of CR oxycodone was $57,702.34 for 1-year treatment of cancer pain [41]. Two studies with respect to chronic pain using a 1-year time horizon reported the costs of CR oxycodone were £3656 and $1426.52 in the UK and Canada separately [42,43]. In our study, the cost-effectiveness was calculated based on the first three days of cancer pain titration. So the costs were much lower than the reported in previous literatures.

Finally, there are intrinsic biases that may influence the results. Potential bias could arise from study heterogeneity, such as in study population and study designs. Only three clinical studies [23,27,29] were conducted outside China, so the risk of publication bias having an effect on our results can not be ruled out. Most of the studies had problems of absence of clear descriptions of randomization, allocation concealment and blinding during clinical trial implementation. Two studies were funded [23,27] by pharmaceutical company. Optimal study design of cancer pain titration should be highlighted to provide better evidence for clinical decision.

**Conclusion**

In conclusion, our results indicate that, from the People’s Republic of China perspective, oxycodone hydrochloride controlled-release tablets is cost-effective compared with morphine.
sulfate sustained-release tablets, and should be an optimization choice for moderate to severe cancer pain titration. Sensitivity analysis shows the results to be reasonably insensitive to variability in key assumptions and variables. The model that we have presented is compliant with the current health economic guidelines. Future studies using real-world data are required to confirm our findings.

Fig 10. Funnel plot of anorexia.
https://doi.org/10.1371/journal.pone.0231763.g010

Table 3. Probability used for cost-effectiveness decision tree.

| Event                     | Probability (%) | P    |
|---------------------------|-----------------|------|
|                            | CR oxycodone group | CR morphine group |      |
| Efficacy                  |                  |                  |      |
| 24h pain control rate     | 64               | 57.45            | 0.33 |
| 48h pain control rate     | 38.89            | 45               | 0.69 |
| 72h pain control rate     | 36.36            | 27.27            | 0.64 |
| Safety                    |                  |                  |      |
| Constipation              | 19.09            | 29.63            | <0.00001 |
| Nausea and vomiting       | 21.7             | 27.4             | 0.005 |
| Pruritus                  | 7.67             | 7.79             | 0.99 |
| Urinary retentron         | 1.05             | 3.01             | 0.09 |
| Anorexia                  | 3.07             | 3.25             | 0.97 |

https://doi.org/10.1371/journal.pone.0231763.t003
Table 4. Total costs of treatment for cost-effectiveness decision tree.

| Resource            | CR oxycodone group | SR morphine group |
|---------------------|--------------------|-------------------|
| 24h pain control    | 17.04              | 9.05              |
| 48h pain control    | 29.07              | 15.68             |
| 72h pain control    | 36.23              | 20.15             |
| Pain control failure| 38.54              | 22.46             |

https://doi.org/10.1371/journal.pone.0231763.t004

Table 5. Cost-effectiveness analysis based on a decision tree.

| Titration strategy | Costs per patient for cancer pain titration ($) | Pain control rate of cancer pain titration |
|--------------------|-----------------------------------------------|------------------------------------------|
| CR oxycodone       | 23.27                                         | 0.8600                                   |
| SR morphine        | 13.31                                         | 0.8298                                   |

$1 = 6.7518¥$

https://doi.org/10.1371/journal.pone.0231763.t005

Fig 11. Cost-effectiveness acceptability curve.

https://doi.org/10.1371/journal.pone.0231763.g011
Fig 12. Scatter plot: incremental cost-effectiveness based on 1000 Monte Carlo simulations.

https://doi.org/10.1371/journal.pone.0231763.g012

Table 6. Incremental cost-effectiveness ratio of CR oxycodone compared with SR morphine for each variation of input parameter in sensitivity analysis.

| Variable                       | Costs($) | ICER per unit ($) |
|--------------------------------|----------|-------------------|
|                                | CR oxycodone group | SR morphine group |
| Titration strategy             |           |                   |
| Titration dose of CR oxycodone 20mg-40mg-80mg | 24.51     | 14.00             | 348.05 |
| Titration dose of CR oxycodone 10mg-20mg-30mg | 11.77     | 11.75             | 0.63  |
| Titration dose of CR oxycodone 10mg-20mg-40mg | 12.39     | 12.37             | 0.51  |
| Drug-acquisition costs($)      |           |                   |
| CR oxycodone +100%             | 45.45     | 13.31             | 1064.13 |
| CR oxycodone +15%              | 26.59     | 13.31             | 439.82  |
| SR morphine -15%               | 23.27     | 11.51             | 389.27  |
| Adverse drug reactions treatment +100% | 23.43     | 13.56             | 326.78  |
| Adverse drug reactions treatment -50% | 23.19     | 13.18             | 331.33  |

https://doi.org/10.1371/journal.pone.0231763.t006
Supporting information

S1 Checklist. (DOC)

S1 File. (DOC)

Acknowledgments

The authors thank Juan Li, M.D. (Department of Medical Oncology, Sichuan Cancer Hospital & Institute), for her useful assistance in clinical.

Author Contributions

Conceptualization: Junxiang Zhou.

Data curation: Junxiang Zhou, Yixin Wang, Gang Jiang.

Investigation: Junxiang Zhou, Yixin Wang.

Methodology: Junxiang Zhou.

Project administration: Junxiang Zhou, Gang Jiang.

Validation: Junxiang Zhou, Yixin Wang, Gang Jiang.

Writing – original draft: Junxiang Zhou.

Writing – review & editing: Junxiang Zhou, Yixin Wang, Gang Jiang.

References

1. Ovayolu Ö, Ovayolu N, Aytaç S, Serçe S, Sevinc A. Pain in cancer patients: pain assessment by patients and family caregivers and problems experienced by caregivers. Support Care Cancer 23 (7):1857–64, 2015 https://doi.org/10.1007/s00520-014-2540-5 PMID: 25471183

2. Cluxton C. The Challenge of Cancer Pain Assessment. Ulster Med J 88(1):43–46, 2019 PMID: 30675079

3. Li Z, Aninditha T, Greene B, Francis J, Renato P, Serrie A, et al. Burden of cancer pain in developing countries: a narrative literature review. Clinicoecon Outcomes Res 10:675–91, 2018 https://doi.org/10.2147/CEO R.S181192 PMID: 30464561

4. Kurita GP, Tange UB, Farholt H, Sonne NM, Strömgren AS, Ankersen L, et al. Pain characteristics and management of inpatients admitted to a comprehensive cancer centre: a cross-sectional study. Acta Anaesthesiol Scand 57(4):518–25, 2013 https://doi.org/10.1111/aas.12068 PMID: 23336265

5. Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res 9:515–34, 2016 https://doi.org/10.2147/JPR.S97759 PMID: 27524918

6. Zecca E, Brunelli C, Bracchi P, Biancofiore G, De Sangro C, Bortolussi R, et al. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial. J Pain Symptom Manage 52(6):783–794, 2016 https://doi.org/10.1016/j.jpainsymman.2016.05.030 PMID: 27742577

7. Schmidt-Hansen M, Bennett MI, Arnold S, et al. Oxycodone for cancer-related pain. Cochrane Database Syst Rev 8:CD003870, 2017 https://doi.org/10.1002/14651858.CD003870.pub6 PMID: 28829910

8. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Adult cancer pain Version 1. 2018. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed 03 June 2018.

9. Takahashi Y, Iseki M. Sustained-release Opioids: Morphine, Oxycodone and Tapentadol. Masui 64 (11):1139–1140, 2015 PMID: 26689063
10. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58–68, 2012 https://doi.org/10.1016/S1470-2245(12)70040-2 PMID: 22300860

11. Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, et al. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig. 28(7):399–407, 2008 https://doi.org/10.2165/00044011-200828070-00001 PMID: 18544000

12. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European palliative care research collaborative guidelines project. Palliat Med 25(5):402–09, 2011 https://doi.org/10.1177/0269216310392102 PMID: 21708848

13. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 25(5):471–77, 2011 https://doi.org/10.1177/0269216310387962 PMID: 21708853

14. Stefani S, Saggia M, Naves A, Vasconcellos JF, Teich V. Extended-Release Oxycodone Hydrochloride (Oxycontin®) for Cancer Pain Management: a Cost Analysis from the Brazilian Public and Private Healthcare Systems Perspectives. Value Health 18(7):A445, 2015

15. Neufeld NJ, Elnahal SM, Alvarez RH. Cancer pain: a review of epidemiology, clinical quality and value impact. Future Oncol 13(9):833–41, 2017 https://doi.org/10.2217/fon-2016-0423 PMID: 27875910

16. National Bureau of Statistics of China. Statistical Communiqué of the People’s Republic of China on the 2017 National Economic and Social Development. 2018. http://www.stats.gov.cn/english/PressRelease/201802/20180228_1585666.html. Accessed 08 January 2019.

17. WHO. Cancer pain relief: with a guide to opioid availability. 2nd ed. 1996. http://apps.who.int/iris/bitstream/10665/57896/1/9241544821.pdf. Accessed 03 June 2018.

18. Higgins J, Green S. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011.http://handbook.cochrane.org/. Accessed 16 July 2018.

19. Doublet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 5: 157–77, 1985 https://doi.org/10.1177/0272989X8500500205 PMID: 3831638

20. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 (5): 479–500, 2000 https://doi.org/10.2165/00044011-200017050-00006 PMID: 10977389

21. Cao Q, Wang LX. The analysis of the two different opioid efficacy in the elderly cancer patients and its safety. Journal of Practical Medical Techniques 22(4):360–61, 2015

22. Gao WY, Gu AL, Zhu M, et al. Oxycodone hydrochloride sustained-release sustained tablets and morphine sulfate sustained-release tablets for advanced malignancy severe pain. Journal of Basic and Clinical Oncology 25(6):524–26, 2012

23. Heiskanen T, Kaleo E. Controlled-release oxycodone and morphine in cancer related pain. Pain 73 (1):37–45, 1997 https://doi.org/10.1016/s0304-3959(97)00072-9 PMID: 9414055

24. Huang MQ, Li CF, Kong FL, et al. Clinical efficacy of oxycodone hydrochloride sustained release tablets in the treatment of pain in advanced cancer. Anhui Medical and Pharmaceutical Journal 19(10):2022–23, 2015

25. Li XO, Lv J, Jin Z. Clinical observation of oxycodone hydrochloride controlled release tablets and morphine sulfate sustained release tablets in the treatment of severe pain in advanced cancer. Journal of Chinese Practical Diagnosis and Therapy 27(12):1216–17, 2013

26. Lin XH, Xu JP, Mai YZ. The efficacy and safety observation of oxycodone retard tablets in the treatment of moderately severe pain. China Medicine and Pharmacy 3(9):78–79, 2013

27. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2(3):239–49, 1998 https://doi.org/10.1016/s1090-3801(98)90020-9 PMID: 15102384

28. Ren LP. The pain relief and the quality of life of patients with moderate to severe cancer pain after taking controlled-release tablets of oxycodone hydrochloride and sustained-release tablets of morphine sulfate. Word Latest Medicine Information 12(9):12–15, 2012

29. Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett R, et al. Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J Pain Symptom Manage 49(2):161–72, 2015 https://doi.org/10.1016/j.jpainsymman.2014.05.021 PMID: 24975432

30. Song YH. Effectiveness evaluation of oxycodone hydrochloride sustained release tablets and morphine sulfate sustained release tablets for severe cancer pain. China PracMed 10(11):150–51, 2015

31. Sun YY, Chen XY, Wang KS, et al. Curative effect analysis of oxycodone and MS contin in the treatment of severe cancerous pain. Cancer Research and Clinic 25(1):36–40, 2013
32. Tu XS, Hu LX. Oxycodone hydrochloride sustained release tablets compared with morphine sulfate sustained release tablets in the treatment of advanced moderate to severe cancer pain. Journal of China Prescription Drug 13(10):88–89, 2015

33. Wang P, Liu Y, Wang T, et al. The observation of curative effect of oxycodone hydrochloride controlled-release tablets in management of moderate and severe cancer pain. Modern Oncology 16(11):1983–85, 2008

34. Ye YM, Xiao XX. Analysis of efficacy and adverse reactions of oxycodone hydrochloride controlled-release tablet and morphine sulfate sustained-release tablets in the treatment of 83 cases of patients with severe cancer pain. Medical Frontier 2(8):69–70, 2012

35. Yu H, Liang LS, Wang JF, et al. Comparison of the effect of Oxycodone and Morphine controlled-release tablets in the treatment of visceral cancer pain. Chin J Curr Adv Gen Surg 12(9):769–811, 2009

36. Yu XH, Wu DG, Yang JF, et al. Curative effect of oxycodone hydrochloride controlled release tablets in the treatment of cancer pain. Chin Hosp Pharm J 27(9):1277–78, 2007

37. Zhang XQ. Analgesic effect analysis of three opioids for patients with advanced cancer pain. Medical Frontier 6(6):164–65, 2016

38. Zhang YY, Han T, Wang Y, et al. Effect of the Titration of Oxycodone Controlled-release Tablets on Moderate Pain. J Med Res 40(4):52–54, 2011

39. Xie XM, Luo LJ, Zhang HL. Clinical efficacy of oxycodone hydrochloride in the treatment of elderly patients with cancer pain. Chinese Community Doctors 34(24):65–67, 2018

40. WHO. Thresholds for the cost–effectiveness of interventions: alternative approaches. 2015. http://www.who.int/bulletins/volumes/93/2/14-138206/en/. Accessed 08 January 2019.

41. Soto MH, Sanchez K, Escobar JY, Constanzo A, Fernandez Z, Melendez C. Cost-Effectiveness Analysis of Oxycodone Lp An Opioid Analgesic for Patients With Moderate To Severe Pain Secondary To Cancer In Mexico. Value Health 17(7):A532, 2014

42. Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ 15(4):724–36, 2012 https://doi.org/10.3111/13696998.2012.670174 PMID: 22364286

43. Goeree R, Goeree J. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. J Med Econ 19(3):277–91, 2016 https://doi.org/10.3111/13696998.2015.1116992 PMID: 26535790